SYN608 / SynRx Therap - LARVOL DELTA

First-in-human study of oral PARG inhibitor SYN608 in advanced solid tumors (AACR 2026) - P1 | "Prior PARP inhibitor therapy is permitted, while prior treatment with a PARG inhibitor is excluded. Enrollment initiated in August 2025."

First-in-human • Metastases • P1 data • Oncology • Solid Tumor • BRCA • HRD

Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=105 | Not yet recruiting | Sponsor: Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd

New P1 trial • Platinum resistant • Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA